Table of Contents
and head of the Roche Venture Fund. Prior to that, Ms. Nuechterlein served as general counsel for SangStat, Inc. She currently serves on the board of directors for Lysosomal
Therapeutics Inc. Ms. Nuechterlein holds a B.A. from Valparaiso University and a J.D. from University of Michigan. Ms. Nuechterlein was appointed to serve on our board of
directors based upon her extensive experience in the pharmaceutical and biotechnology industry, including ten years of experience as an attorney in the pharmaceutical and biotechnology industry and
over ten years of experience as an investor in life science companies.
Bong Koh has served as a member of our board of directors since June 2015. Since 2009, Dr. Koh has been a partner at Venrock, a
venture capital firm where he manages Venrock's public and cross-over biotechnology fund. Dr. Koh earned his B.A. from Yale University, his M.D. from the University of California, San
Francisco, and an M.B.A. from Harvard Business School. Our board of directors believes that Dr. Koh should serve as a director based on his extensive experience in the biotechnology industry
providing leadership in biotechnology investments.
Frank Verwiel has served as a member of our board of directors since December 2015. Dr. Verwiel was the President and CEO of
Aptalis Pharma Inc. from 2005 to 2014, where he also served on the board of directors. He currently serves as a member of the board of directors of Achillion Pharmaceuticals, Inc., a
position he has held since December 2015, and is an observer to the board of directors of Bavarian Nordic A/S. Dr. Verwiel previously served on the board of directors of
InterMune, Inc. from 2011 to 2014. Dr. Verwiel was also a director of the Biotechnology Industry Organisation. Dr. Verwiel received his M.D. from Erasmus University, Rotterdam and
his M.B.A. from INSEAD. Our board of directors believes that Dr. Verwiel should serve as a director based upon his scientific acumen and his over 25 years of strategic, operational and
international experience in the pharmaceutical industry.
Scientific Advisory Board
We have established a scientific advisory board. We regularly seek advice and input from these experienced leaders on matters related
to our research and development programs. Our scientific advisory board consists of experts across a range of key disciplines relevant to our programs and science. We intend to continue to leverage
the broad expertise of our advisors by seeking their counsel on important topics relating to our research and development programs. The members of our scientific advisory board have entered into
agreements with us covering confidentiality and non-disclosure matters. Our scientific advisory board currently consists of our Chief Scientific Officer Dr. Kaspar (Nationwide Children's Hospital),
Christian Lorson, Ph.D. (University of Missouri), Charlotte Sumner, M.D. (Johns Hopkins University) and Arthur Burghes, Ph.D. (Ohio State University).
Board Composition and Election of Directors
Our board of directors currently consists of eight members, each of whom serve as directors pursuant to the board composition
provisions of our third amended and restated certificate of incorporation and our third amended and restated investor rights agreement, as amended, or IRA, that we entered into with certain of our
investors, which is further described under "Certain Relationships and Related Party Transactions" in this prospectus. The IRA provides that our board of directors shall include (i) one
director who is serving as our Chief Executive Officer, which is currently Mr. Nolan, (ii) one director to be a representative of the holders of our common stock, designated by the
holders of a majority of our common stock, which is currently Dr. Verwiel,
(iii) one director to be a representative of the holders of our Class B-1 preferred stock, designated by PBM Capital Investments, LLC, which is currently Mr. Manning, and
(iv) two directors to be